{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:06:56Z","timestamp":1792840016558,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.cgh.2022.04.023","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T05:11:13Z","timestamp":1651813873000},"page":"970-977.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issah","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2022.04.023_bib1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","article-title":"Epidemiology and natural history of non-alcoholic fatty liver disease","volume":"65","author":"Fazel","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.cgh.2022.04.023_bib2","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.04.023_bib3","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.04.023_bib4","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.04.023_bib5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.04.023_bib6","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.14309\/ajg.0000000000001386","article-title":"The changing epidemiology of liver disease among US children and adolescents from 1999 to 2016","volume":"116","author":"Li","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.04.023_bib7","first-page":"1676","article-title":"Global burden of non-alcoholic fatty liver disease (NAFLD) and cirrhosis among adolescents and young adults","volume":"5","author":"Paik","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.04.023_bib8","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/hep4.1765","article-title":"Poor awareness of liver disease among adults with NAFLD in the United States","volume":"5","author":"Alqahtani","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2022.04.023_bib9","doi-asserted-by":"crossref","first-page":"e1456","DOI":"10.1016\/j.cgh.2021.06.048","article-title":"A\u00a0global survey of physicians knowledge about nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.04.023_bib10","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.cgh.2021.11.004","article-title":"Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the global non-alcoholic steatohepatitis (NASH)\/ non-alcoholic fatty liver disease (NAFLD) registry","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.04.023_bib11","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/hep4.1581","article-title":"Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient-reported outcomes","volume":"4","author":"Younossi","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2022.04.023_bib12","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/hep.30782","article-title":"Report on the AASLD\/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD","volume":"70","author":"Rinella","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.04.023_bib13","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.cgh.2019.01.001","article-title":"Validation of chronic liver disease questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.04.023_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2015-000069","article-title":"Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH)","volume":"3","author":"Chawla","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.cgh.2022.04.023_bib15","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.14309\/ajg.0000000000000375","article-title":"Patients with nonalcoholic steatohepatitis experience severe impairment of health-related quality of life","volume":"114","author":"Younossi","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.04.023_bib16","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","article-title":"The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.04.023_bib17","article-title":"Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis","volume":"2","author":"McSweeney","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cgh.2022.04.023_bib18","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.cgh.2019.02.024","article-title":"Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.04.023_bib19","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"28","key":"10.1016\/j.cgh.2022.04.023_bib20","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.3748\/wjg.v25.i28.3669","article-title":"Importance of fatigue and its measurement in chronic liver disease","volume":"25","author":"Gerber","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.04.023_bib21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"STELLAR-3 and STELLAR-4 Investigators. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.04.023_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.cgh.2022.04.023_bib23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.04.023_bib24","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/hep.30946","article-title":"The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH","volume":"70","author":"Loomba","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.04.023_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12955-016-0420-z","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of health related quality of life (HRQOL)","volume":"14","author":"Golabi","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.cgh.2022.04.023_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.psym.2010.12.019","article-title":"Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C","volume":"52","author":"Weinstein","year":"2011","journal-title":"Psychosomatics"},{"key":"10.1016\/j.cgh.2022.04.023_bib27","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2018.12.016","article-title":"Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation","volume":"17","author":"Huber","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.04.023_bib28","unstructured":"Younossi ZM, Stepanova M, Nader F, et\u00a0al. Assessment of patient-reported outcomes (PROs) in patients with non-alcoholic steatohepatitis (NASH) treated with obeticholic acid (OCA): results from REGENERATE phase 3 clinical trial. Presented at: American Society of the Study of Liver Diseases Liver Meeting; 2019; November 8\u201312, 2019; Boston, Massachusetts."},{"key":"10.1016\/j.cgh.2022.04.023_bib30","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jpainsymman.2009.09.026","article-title":"Qualities of fatigue and associated chronic conditions among older adults","volume":"39","author":"Hardy","year":"2010","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.cgh.2022.04.023_bib31","unstructured":"Golabi P, Paik JM, Henry L, et\u00a0al. Among patients with non-alcoholic fatty liver disease (NAFLD) presence of fatigue is associated with higher mortality. Poster presented at: American Association for the Study of Liver Disease Liver Meeting 2021; November 12\u201315, 2021; online."},{"key":"10.1016\/j.cgh.2022.04.023_bib32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1037\/hea0000598","article-title":"Is fatigue a disease-specific or generic symptom in chronic medical conditions?","volume":"37","author":"Menting","year":"2018","journal-title":"Health Psychol"},{"key":"10.1016\/j.cgh.2022.04.023_bib33","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jhep.2010.05.036","article-title":"Central nervous system dysfunction in primary biliary cirrhosis and its relationship to symptoms","volume":"53","author":"McDonald","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.04.023_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/liv.13919","article-title":"Fatigue in chronic liver disease: new insights and therapeutic approaches","volume":"39","author":"Swain","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2022.04.023_bib35","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.it.2018.05.002","article-title":"Liver-microbiome axis in health and disease","volume":"39","author":"Adolph","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.cgh.2022.04.023_bib36","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cgh.2008.04.013","article-title":"A\u00a0pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis","volume":"6","author":"Hollingsworth","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.04.023_bib37","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1038\/ctg.2017.34","article-title":"Primary biliary cholangitis alters functional connections of the brain\u2019s deep gray matter","volume":"8","author":"Mosher","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cgh.2022.04.023_bib38","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/gut.2003.016766","article-title":"Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels","volume":"53","author":"Forton","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2022.04.023_bib39","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/apt.13797","article-title":"Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging","volume":"44","author":"Grover","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.04.023_bib40","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.cld.2017.03.011","article-title":"Patient-reported outcomes and fatigue in patients with chronic hepatitis C infection","volume":"21","author":"Golabi","year":"2017","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2022.04.023_bib41","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2015.07.035","article-title":"Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection","volume":"14","author":"Gerber","year":"2016","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522004487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522004487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:43:23Z","timestamp":1761543803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356522004487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1542356522004487"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2022.04.023","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2022.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the AGA Institute","name":"copyright","label":"Copyright"}]}}